Publications by authors named "Donald Thornton"

Claim this Profile
A
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.
Michael Michael, Yung-Jue Bang, Young Suk Park, Yoon-Koo Kang, Tae Min Kim, Donald Thornton

Target Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.
Byung-Sik Cho, Zhihong Zeng, Hong Mu, Zhiqiang Wang, Sergej Konoplev, Donald E Thornton

Blood· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer.
Matthew D Galsky, Nicholas J Vogelzang, Paul Conkling, Eyas Raddad, John Polzer, Donald Thornton

Clin Cancer Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography.
Karen E Pollok, Michael Lahn, Nathan Enas, Ann McNulty, Jeremy Graff, Donald Thornton

J Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.
Nwabundo Nwankwo, Zhe Zhang, Ting Wang, Connie Collins, Lee Resta, Donald Thornton

Invest New Drugs· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Nicholas Butowski, Susan M Chang, Kathleen R Lamborn, Mei-Yin Polley, Russell Pieper, Donald E Thornton

Neuro Oncol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
Nicholas Butowski, Susan M Chang, Kathleen R Lamborn, Mei Yin Polley, R Parvataneni, Donald E Thornton

Neuro Oncol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
Wolfgang Wick, Vinay K Puduvalli, Marc C Chamberlain, Martin J van den Bent, Antoine F Carpentier, Donald E Thornton

J Clin Oncol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.
Teri N Kreisl, Svetlana Kotliarova, John A Butman, Paul S Albert, Lyndon Kim, Donald Thornton

Neuro Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of enzastaurin in patients with recurrent gliomas.
Teri N Kreisl, Lyndon Kim, Kraig Moore, Paul Duic, Svetlana Kotliarova, Donald Thornton

Clin Cancer Res· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
D Ross Camidge, S Gail Eckhardt, Lia Gore, Cindy L O'Bryant, Stephen Leong, Donald Thornton

Anticancer Drugs· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Michael J Robertson, Brad S Kahl, Julie M Vose, Sven de Vos, Mary Laughlin, Donald Thornton

J Clin Oncol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas.
Shuyu Li, Mark Phong, Michael Lahn, Leslie Brail, Susan Sutton, Donald Thornton

Biol Direct· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization and cost of health care services associated with primary malignant brain tumors in the United States.
Lucie Kutikova, Lee Bowman, Stella Chang, Stacey R Long, Donald E Thornton

J Neurooncol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Michael A Carducci, Luna Musib, Merrill S Kies, Roberto Pili, Mylene Truong, Donald E Thornton

J Clin Oncol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Lisa J Green, Philip Marder, Chad Ray, Carolyn A Cook, Susan Jaken, Donald Thornton

Clin Cancer Res· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Jeremy R Graff, Ann M McNulty, Kimberly Ross Hanna, Bruce W Konicek, Rebecca L Lynch, Donald Thornton

Cancer Res· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.
Mario A Eisenberger, Menachem Laufer, Nicholas J Vogelzang, Oliver Sartor, Donald Thornton

Urology· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A liver transplant patient.
Donald Thornton

Hepatobiliary Pancreat Dis Int· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer.
Martin J Edelman, David R Gandara, Petr Hausner, Valerie Israel, Donald Thornton

Lung Cancer· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
James P Stevenson, Weijing Sun, Maryann Gallagher, Robert Johnson, David Vaughn, Donald Thornton

Clin Cancer Res· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis